CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

iloprost

Trade name: ventavis

Small moleculeapprovedOrphan Drug FDA

Approved

Dec 29, 2004

Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost constricts the ilium and fundus circular smooth muscle as strongly as prostaglandin E2 (PGE2) itself. Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time. All of these properties help to antagonize the pathological changes that take place in the small pulmonary arteries of patients with pulmonary hypertension. Used for the treatment of pulmonary arterial hypertension. — NCATS

Clinical trial activity

73 trials · 68 clinical orgs · 4 marketing orgs

Phase 1
12
Phase 2
40
Phase 3
17
Phase 4
9

Earliest trial started Dec 1, 1995 (NCT00004786)

Timeline

1990s

  1. Jun 1, 1990

    Schering AG — IND Organization

  2. Jun 1, 1990

    Schering AG — IND Organization

  3. Jan 1, 1995

    Earliest Phase 3 Sponsor(trial)

  4. Jan 1, 1997

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Aug 17, 2004

    Orphan Drug Designation

  2. Dec 29, 2004

    CoTherix — Earliest FDA Approval

  3. Dec 29, 2004

    CoTherix — NDA Organization

  4. Dec 29, 2004

    Actelion — Marketing Organization

  5. Dec 29, 2004

    Actelion — NDA Secondary Org

  6. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Feb 13, 2024

    BTG — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewDec 29, 2004

Chemistry & pharmacology

Loading structure…

SMILES

CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
Mol. weight
360.4871 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Parenteral, Topical
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

Yes

Sources

Also known as

  • ciloprost
  • ciloprost
  • ciloprost
  • endoprost
  • illoprost
  • ilomedin
  • ilomedin
  • ilomedin
  • iloprost
  • iloprost
  • iloprost
  • iloprost
  • iloprost
  • iloprost
  • iloprost
  • iloprost
  • iloprost
  • iloprost
  • iloprost
  • iloprost
  • ventavis
  • ventavis
  • ventavis
  • ventavis
  • zk-00036374
  • zk-00036374
  • zk36374
  • zk 36374
  • zk-36374

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07263958N/ADec 10, 2025University of Sao Paulo
NCT06429930Phase 1Sep 1, 2024Novotech, Pharmosa Biopharm Inc.
NCT06319274Phase 2Apr 15, 2024University of Copenhagen
NCT05938946Phase 1Aug 30, 2023Novotech, Pharmosa Biopharm Inc.
NCT05411107Phase 2Jan 23, 2023National Cancer Institute (NCI), Northwestern University
NCT04927039N/AJun 24, 2021Yonsei University
NCT04543682Phase 1/Phase 2 (Phase 2)Jan 31, 2021Humboldt University
NCT04598191N/ANov 4, 2020Yonsei University
NCT04583046N/AOct 31, 2020Yonsei University
NCT04420741Phase 2Jun 1, 2020University of Copenhagen
NCT04445246Phase 2May 23, 2020Hamad Medical Corporation
NCT04040322Phase 3Oct 31, 2019Civi Biopharma, Inc., Eicos Sciences, Inc.
NCT04123444Phase 2/Phase 3 (Phase 3)Oct 28, 2019Government of Denmark, Innovation Fund Denmark, University of Copenhagen
NCT03903939Phase 2May 22, 2019Aalborg University, Aarhus University, University of Copenhagen, University of Oslo, University of Southern Denmark
NCT03788837Phase 3Apr 17, 2019Assistance Publique - Hôpitaux de Paris
NCT03867097Phase 2Mar 4, 2019Civi Biopharma, Inc., Eicos Sciences, Inc.
NCT03111212Phase 3Jun 1, 2018University of Tuebingen
NCT03936140N/AJan 4, 2018Catholic University of Korea
NCT03620526Phase 4Nov 29, 2017National Taiwan University
NCT03044314Phase 4Jun 1, 2017Actelion, Duke University
Showing 20 of 73 trials
Page 1 / 4

Organizations

Research & Development (68)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ActelionFor profit15952004
University of CopenhagenAcademic/Hospital8622010
BayerFor profit7441998
Yonsei UniversityAcademic/Hospital5512015
Duke UniversityAcademic/Hospital3222006
Jiao Tong UniversityAcademic/Hospital3322007
National Cancer Institute (NCI)Government3222001
Catholic University of KoreaAcademic/Hospital2122010
Civi Biopharma, Inc.For profit2022019
CoTherixFor profit2012004
Eicos Sciences, Inc.For profit2222019
Humboldt UniversityAcademic/Hospital2211997
Justus Liebig University GiessenAcademic/Hospital2122006
Northwestern UniversityAcademic/Hospital2022015
NovotechFor profit2012023
Pharmosa Biopharm Inc.For profit2212023
Thrombologic ApSFor profit2212010
University of HeidelbergAcademic/Hospital2222005
University of OklahomaAcademic/Hospital2222006
University of PittsburghAcademic/Hospital2021995
68 organizations
Page 1 / 4

Marketing (5)

OrganizationOrg typeRelationshipDate
ActelionFor profitMKTGDec 29, 2004
ActelionFor profitNDA2Dec 29, 2004
BTGFor profitMKTGFeb 13, 2024
CoTherixFor profitNDADec 29, 2004
Schering AGFor profitINDJun 1, 1990